Literature DB >> 1796046

Differences in transport rate of oxytocin and vasopressin analogues across proximal and distal isolated segments of the small intestine of the rat.

S Lundin1, N Pantzar, A Broeders, M Ohlin, B R Weström.   

Abstract

The transmural intestinal passage of some oxytocin and vasopressin analogues (oxytocin, OT; [Mpa1, D-Arg8]vasopressin, dDAVP; [Mpa1, Tyr (OMe)2, carba6]oxytocin, carbetocin; [Mpa1, D-Tyr (OEt)2, Thr4, Orn8]vasotocin, antocin II; [Mpa1, D-Tyr (OEt)2, Thr4, desPro7Orn8Gly9NH2]tocinoic acid-NH(CH2)3NH2, desPOG-antocin II-NH(CH2)3NH2) was studied using isolated proximal and distal segments in the rat. All peptides (measured as peptide-like immunoreactivity) displayed a higher transport rate across distal intestinal segments as determined by radioimmunoassay (RIA). The smallest peptide, des POG-antocin II-NH(CH2)3NH2, was transported at the fastest rate. No correlation of lipophilicity with transport rate was observed. Determination of the amount of peptide remaining in the mucosal media at the end of the incubation period by HPLC did not reveal any visible degradation products. However, the large difference in transport rate between [3H]OT and immunoreactive OT indicates mucosal metabolism of this peptide. [3H]d-DAVP was distributed in a larger mucosal volume than the extracellular space marker [3H]inulin, indicating tissue uptake, but was too low (less than 100% of buffer concentration) to make an active transport mechanism likely. The differences in peptide transport rates between proximal and distal intestinal segments are most likely due to a higher distal paracellular permeability despite a decreased absorptive surface area at this region.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1796046     DOI: 10.1023/a:1015803813026

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neurohypophyseal hormones by kidney preparations of various species.

Authors:  R Walter
Journal:  Biochim Biophys Acta       Date:  1976-01-23

Review 2.  Transport of peptide and protein drugs across biological membranes.

Authors:  J C Verhoef; H E Boddé; A G de Boer; J A Bouwstra; H E Junginger; F W Merkus; D D Breimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  Development of an immunoassay for glypressin, an N-terminal extended vasopressin analogue.

Authors:  M Ohlin; U Alkner
Journal:  J Immunoassay       Date:  1988

4.  Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans.

Authors:  H Vilhardt; S Lundin
Journal:  Gen Pharmacol       Date:  1986

5.  Protracted milk-ejecting effect of some oxytocin analogues in rats.

Authors:  T Barth; M Flegel; K Jost
Journal:  Endocrinol Exp       Date:  1976-03

6.  Studies on the transport of enkephalin-like oligopeptides in rat intestinal mucosa.

Authors:  G A Kerchner; L E Geary
Journal:  J Pharmacol Exp Ther       Date:  1983-07       Impact factor: 4.030

7.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

Authors:  P Artursson
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

8.  Absorption of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in rabbits.

Authors:  S Lundin; H Vilhardt
Journal:  Acta Endocrinol (Copenh)       Date:  1986-07

9.  Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes.

Authors:  S L Stephenson; A J Kenny
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

10.  Mechanisms of polyethylene glycol 400 permeability of perfused rat intestine.

Authors:  P Krugliak; D Hollander; T Y Ma; D Tran; V D Dadufalza; K D Katz; K Le
Journal:  Gastroenterology       Date:  1989-11       Impact factor: 22.682

View more
  7 in total

1.  Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man.

Authors:  L d'Agay-Abensour; A Fjellestad-Paulsen; P Höglund; Y Ngô; O Paulsen; J C Rambaud
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Colonic absorption and bioavailability of the pentapeptide metkephamid in the rat.

Authors:  P Langguth; G Breves; A Stöckli; H P Merkle; S Wolffram
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

3.  Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid.

Authors:  P Langguth; H P Merkle; G L Amidon
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

4.  Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP).

Authors:  A H Kahns; A Buur; H Bundgaard
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

5.  Absorption of an oxytocin antagonist (antocin) and a vasopressin analogue (dDAVP) through a standardized skin erosion in volunteers.

Authors:  S Lundin; P Svedman; P Höglund; K Jönsson; A Broeders; P Melin
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

6.  Mechanisms of increased intestinal [51Cr]EDTA absorption during experimental colitis in the rat.

Authors:  N Pantzar; G M Ekström; Q Wang; B R Weström
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

7.  Intestinal transepithelial permeability of oxytocin into the blood is dependent on the receptor for advanced glycation end products in mice.

Authors:  Haruhiro Higashida; Kazumi Furuhara; Agnes-Mikiko Yamauchi; Kisaburo Deguchi; Ai Harashima; Seiichi Munesue; Olga Lopatina; Maria Gerasimenko; Alla B Salmina; Jia-Sheng Zhang; Hikari Kodama; Hironori Kuroda; Chiharu Tsuji; Satoshi Suto; Hiroshi Yamamoto; Yasuhiko Yamamoto
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.